
First patient enrollment for ALS treatment trial
Ferrer, a pharmaceutical company focused on neurological disorders and pulmonary vascular and interstitial lung diseases, has enrolled the first patient in its Amyotrophic Lateral Sclerosis (ALS) Deceleration with ORal Edaravone (ADORE), FNP122 Phase III clinical trial. The trial The trial will enrol about 300 patients across European countries and it will evaluate… Read More
